BrainsWay (Nasdaq:BWAY) announced today that it launched an investigator-initiated study (IIS) program for its Deep TMS technology.
The company designed the program to support further research for Deep TMS (transcranial magnetic stimulation) by the clinical research community. According to a news release, BrainsWay plans to utilize data collaboration and equipment loan initiatives. The company accepts applications through July 3, 2023.
BrainsWay said it aims for the program to aid investigators interested in advancing current knowledge about Deep TMS. The company encourages early-career investigators and those utilizing BrainsWay’s patented Deep TMS H4 coil.
Deep TMS holds three FDA-cleared indications as a noninvasive neurostimulation treatment for mental health disorders. Current indications include major depressive disorder, obsessive-compulsive disorder and smoking addiction. BrainsWay has additional clinical trials underway for the platform in treating various psychiatric, neurological and addiction disorders.
“With superior science and superior evidence, BrainsWay continues to lead the TMS field with its IIS Program,” said Colleen Hanlon, VP of medical affairs. “Our goal is to support researchers in their efforts to advance neuroscience research by facilitating Deep TMS data development and furthering access to our novel equipment.
“The partnerships with academia that will be achieved through this program are a further testament to our longstanding commitment to moving the field forward by improving health and transforming even more patients’ lives.”